JiangXi Tianxin Pharmaceutical Co., Ltd. (SHA:603235)
China · Delayed Price · Currency is CNY 26.12
+0.18 (0.69%)
At close: May 8, 2026
SHA:603235 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 520.02 | 591.58 | 651.22 | 475.85 | 622.12 | 743.89 |
Depreciation & Amortization | 189.92 | 189.92 | 153.93 | 138.75 | 127.11 | 110.13 |
Other Amortization | 2.49 | 2.49 | 1.62 | 1.39 | 2.04 | 5.95 |
Loss (Gain) From Sale of Assets | 0.51 | 0.51 | -0 | - | - | 3.33 |
Asset Writedown & Restructuring Costs | 18.33 | 18.33 | 8.62 | 12.45 | 0.9 | 4.89 |
Loss (Gain) From Sale of Investments | -8.93 | -8.93 | -7.68 | -2.07 | -6.63 | 2.28 |
Provision & Write-off of Bad Debts | - | - | 3.46 | -3.16 | -3.23 | 7.03 |
Other Operating Activities | 38.54 | 11.35 | -49.22 | -25.67 | -56.45 | 32.65 |
Change in Accounts Receivable | -194.39 | -194.39 | -239.11 | 7.15 | 63.92 | -167.58 |
Change in Inventory | -3.36 | -3.36 | -117.2 | -20.51 | -68.39 | -75.7 |
Change in Accounts Payable | 24.62 | 24.62 | 128.49 | 82.92 | -51.3 | 62.92 |
Change in Other Net Operating Assets | 4.97 | 4.97 | -32.42 | 84.63 | -26.34 | 107.86 |
Operating Cash Flow | 584.99 | 629.36 | 499.66 | 729.21 | 606.61 | 818.63 |
Operating Cash Flow Growth | -0.34% | 25.96% | -31.48% | 20.21% | -25.90% | -29.65% |
Capital Expenditures | -523.87 | -580.68 | -1,067 | -535.6 | -260.5 | -215.5 |
Sale of Property, Plant & Equipment | 0.57 | 0.57 | 0.27 | - | - | 7.17 |
Investment in Securities | - | - | -479.44 | 230 | -230.5 | - |
Other Investing Activities | -256.14 | 490.62 | 5.46 | 2.45 | 35.66 | -31.21 |
Investing Cash Flow | -779.44 | -89.5 | -1,541 | -303.15 | -455.34 | -239.54 |
Long-Term Debt Issued | - | 262.41 | 312.43 | 100 | 90 | 300 |
Long-Term Debt Repaid | - | -7.63 | -272.42 | -3.17 | -433.71 | -307.49 |
Net Debt Issued (Repaid) | 179.67 | 254.77 | 40.01 | 96.83 | -343.71 | -7.49 |
Issuance of Common Stock | - | - | - | - | 1,540 | - |
Repurchase of Common Stock | - | - | -60.01 | - | - | - |
Common Dividends Paid | -306.03 | -304.82 | -220.19 | -312.42 | -6.83 | -878.47 |
Other Financing Activities | 10.46 | 10.46 | - | - | -26.6 | - |
Financing Cash Flow | -115.91 | -39.59 | -240.19 | -215.59 | 1,162 | -885.96 |
Foreign Exchange Rate Adjustments | -22.19 | -8.97 | 51.71 | 27.77 | 63.37 | -19.98 |
Net Cash Flow | -332.55 | 491.31 | -1,230 | 238.24 | 1,377 | -326.86 |
Free Cash Flow | 61.12 | 48.68 | -567.3 | 193.61 | 346.11 | 603.13 |
Free Cash Flow Growth | - | - | - | -44.06% | -42.61% | -29.92% |
Free Cash Flow Margin | 2.58% | 2.08% | -25.69% | 10.29% | 15.02% | 23.91% |
Free Cash Flow Per Share | 0.14 | 0.11 | -1.30 | 0.44 | 0.84 | 1.53 |
Cash Income Tax Paid | 145.82 | 145.82 | 130.8 | 55.13 | 125.68 | 114.88 |
Levered Free Cash Flow | 103.88 | 28.12 | -715.82 | -28.07 | 176.18 | -619.31 |
Unlevered Free Cash Flow | 106.32 | 28.12 | -714.27 | -26.76 | 180.51 | -611.39 |
Change in Working Capital | -175.88 | -175.88 | -262.28 | 131.67 | -79.24 | -91.53 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.